Legal proceedings for investor compensation claims are advancing for two listed companies.

A court date has been scheduled for the investor compensation lawsuit against Changjiang Pharmaceutical Group Co.,Ltd. (ASX: 300391). The case, represented by lawyer Xu Feng from Shanghai Jiucheng Law Firm, is set to be heard at the Wuhan Intermediate People's Court on July 15, 2026.

Attorney Xu Feng's team has successfully filed multiple claims on behalf of investors in the Changyao Holdings case and is continuing to process further submissions. The legal team is also accepting new mandates from other eligible investors. Notably, there is already a precedent of investors winning compensation in this matter.

On March 18, 2026, Changyao Holdings announced it had received an "Administrative Penalty Decision" from the China Securities Regulatory Commission. Attorney Xu Feng indicates that investors who purchased Changyao Holdings stock between March 30, 2019, and April 30, 2024, and sold or continued to hold it after April 30, 2024, as well as those who bought between April 28, 2022, and November 8, 2025, and sold or held after November 8, 2025, are still eligible to file claims.

In a related development, a new batch of investor compensation claims against Hainan Poly Pharm.Co.,Ltd. (ASX: 300630), also represented by Attorney Xu Feng, was filed with the Haikou Intermediate People's Court on June 30, 2026.

Previously, claims for Poly Pharmaceutical investors represented by Attorney Xu Feng received a first-instance judgment from the Haikou court, resulting in a favorable outcome for the plaintiffs. The legal team continues to accept new cases from other eligible investors.

On March 21, 2025, Poly Pharmaceutical disclosed that it had received an "Administrative Penalty Decision" from the CSRC dated January 4, 2025. The investigation found that Poly Pharmaceutical overstated its 2021 revenue by 514,604,184.72 yuan, representing 34.11% of the disclosed annual revenue, with corresponding overstated costs of 206,585,749.23 yuan, leading to an overstatement of total profit by 308,018,435.49 yuan, or 65.88% of the disclosed figure. For 2022, revenue was overstated by 515,899,077.56 yuan (28.56% of disclosed revenue), with corresponding costs of 128,481,820.04 yuan, resulting in an overstatement of total profit by 387,417,257.52 yuan, or 88.27% of the disclosed amount. The company's 2021 and 2022 annual reports contained false records.

Attorney Xu Feng, a specialist in securities litigation, asserts that investors who purchased Poly Pharmaceutical stock between April 26, 2022, and April 17, 2024, and sold or continued to hold it after April 17, 2024, are still eligible to initiate compensation claims.